Pharmaceuticals News

Browse the latest Pharmaceuticals news. Use the menu or navigation tiles to change industry or topic.

January 22, 2026 07:00 ET | Source: Vivani Medical, Inc.

Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026

Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company’s new Orion cortical stimulation system for visual perception, designed to...
January 22, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 22, 2026 06:00 ET | Source: Tilray Brands, Inc.

Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio

NEW YORK and SAVONA, Italy, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis,...
January 22, 2026 05:00 ET | Source: Resalis Therapeutics SRL

Resalis Therapeutics Appoints Sandor Batkai as Medical Director

Torino, Italy, January 22 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, today announced the appointment of Sandor Batkai, MD, PhD, as Medical Director. Dr....
January 22, 2026 03:00 ET | Source: PulseSight Therapeutics S.A.S

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

PARIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery...
January 21, 2026 22:53 ET | Source: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized...
January 21, 2026 22:30 ET | Source: BioAge Labs, Inc.

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates...
January 21, 2026 20:54 ET | Source: Erasca, Inc.

Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
January 21, 2026 16:15 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
January 21, 2026 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions